ATE344316T1 - Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten - Google Patents

Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten

Info

Publication number
ATE344316T1
ATE344316T1 AT05021001T AT05021001T ATE344316T1 AT E344316 T1 ATE344316 T1 AT E344316T1 AT 05021001 T AT05021001 T AT 05021001T AT 05021001 T AT05021001 T AT 05021001T AT E344316 T1 ATE344316 T1 AT E344316T1
Authority
AT
Austria
Prior art keywords
prevention
substances
treatment
autoimmune disease
autoimmune diseases
Prior art date
Application number
AT05021001T
Other languages
English (en)
Inventor
Alan P Escher
Fengchun Li
Original Assignee
Univ Loma Linda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Loma Linda filed Critical Univ Loma Linda
Application granted granted Critical
Publication of ATE344316T1 publication Critical patent/ATE344316T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Mycology (AREA)
AT05021001T 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten ATE344316T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40165202P 2002-08-06 2002-08-06

Publications (1)

Publication Number Publication Date
ATE344316T1 true ATE344316T1 (de) 2006-11-15

Family

ID=32107846

Family Applications (3)

Application Number Title Priority Date Filing Date
AT05021002T ATE344317T1 (de) 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
AT03808948T ATE386104T1 (de) 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
AT05021001T ATE344316T1 (de) 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT05021002T ATE344317T1 (de) 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
AT03808948T ATE386104T1 (de) 2002-08-06 2003-08-06 Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten

Country Status (10)

Country Link
US (3) US7381711B2 (de)
EP (3) EP1626083B1 (de)
JP (3) JP4301567B2 (de)
CN (3) CN100389192C (de)
AT (3) ATE344317T1 (de)
AU (1) AU2003296892B2 (de)
CA (3) CA2653201C (de)
DE (3) DE60319103T2 (de)
ES (3) ES2300652T3 (de)
WO (1) WO2004034966A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300652T3 (es) * 2002-08-06 2008-06-16 Loma Linda University Sustancias para prevenir y tratar enfermedades autoinmunes.
WO2006047954A1 (en) * 2004-11-04 2006-05-11 Ziyi Cheng The method of obtaining and applying the materials for autoantigen immunological recognition
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
DE602006015373D1 (de) 2005-05-11 2010-08-19 Univ Loma Linda Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
EP2069375B1 (de) 2006-09-28 2012-03-28 Loma Linda University Durch apoptotische Zellen vermittelte Transfektion von Säugetierzellen mit interferierender RNA
JP5726294B2 (ja) 2010-05-28 2015-05-27 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ ジオルガノジハロシランの調製方法
JP2013527203A (ja) 2010-05-28 2013-06-27 ダウ コーニング コーポレーション 有機ハロシランの調製
WO2012021512A2 (en) * 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP2013537162A (ja) 2010-09-08 2013-09-30 ダウ コーニング コーポレーション トリハロシランの調製方法
USRE46657E1 (en) 2010-12-17 2018-01-02 Dow Corning Corporation Method of making a trihalosilane
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
US10813987B2 (en) 2011-09-23 2020-10-27 Loma Linda University Method for inducing a tolerogenic immune response
CN104736547A (zh) 2012-08-13 2015-06-24 道康宁公司 通过使氢、卤硅烷和有机卤化物在铜催化剂上以两步法反应制备有机卤硅烷的方法
CN103116030A (zh) * 2013-01-30 2013-05-22 山东东兴生物科技股份有限公司 一种检测i型糖尿病自身免疫抗体试剂盒及其检测方法
KR102299593B1 (ko) 2013-11-12 2021-09-09 다우 실리콘즈 코포레이션 할로실란의 제조 방법
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6725510B2 (ja) 2014-12-18 2020-07-22 ダウ シリコーンズ コーポレーション アリール官能性シランの製造方法
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019028503A1 (en) * 2017-08-07 2019-02-14 St Vincent's Institute Of Medical Research THERAPY OF DIABETES TYPE 1
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
EP4114446A1 (de) * 2020-03-03 2023-01-11 Aditxt, Inc. Verfahren zur behandlung von hyperglykämie und unterdrückung des auftretens von typ-1-diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators
CN1056380C (zh) * 1998-02-27 2000-09-13 中科院成都地奥制药公司 抑制人体恶性肿瘤生长的反义寡核苷酸
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
JP2000236100A (ja) * 1999-02-17 2000-08-29 Sanyo Electric Co Ltd 半導体素子
AU773279B2 (en) * 1999-04-08 2004-05-20 Johns Hopkins University, The Antigen-specific induction of peripheral immune tolerance
CN1117098C (zh) * 1999-06-25 2003-08-06 北京金赛狮生物制药技术开发有限责任公司 针对囊依赖的淋巴细胞白血病基因的反义核酸的抑癌作用
ES2300652T3 (es) * 2002-08-06 2008-06-16 Loma Linda University Sustancias para prevenir y tratar enfermedades autoinmunes.

Also Published As

Publication number Publication date
CA2649821C (en) 2016-09-20
DE60319103T2 (de) 2009-02-05
CA2653201A1 (en) 2004-04-29
EP1543109B1 (de) 2008-02-13
EP1624053A1 (de) 2006-02-08
CN100389192C (zh) 2008-05-21
EP1543109A2 (de) 2005-06-22
DE60309514T2 (de) 2007-05-10
US20080171713A1 (en) 2008-07-17
EP1626083A1 (de) 2006-02-15
CA2649821A1 (en) 2004-04-29
US7638498B2 (en) 2009-12-29
DE60309513D1 (de) 2006-12-14
EP1626083B1 (de) 2006-11-02
DE60319103D1 (de) 2008-03-27
WO2004034966A3 (en) 2004-07-08
AU2003296892A1 (en) 2004-05-04
ES2275254T3 (es) 2007-06-01
DE60309513T2 (de) 2007-05-03
JP5555431B2 (ja) 2014-07-23
JP2009143945A (ja) 2009-07-02
CA2494888C (en) 2009-03-31
JP4301567B2 (ja) 2009-07-22
US20080171714A1 (en) 2008-07-17
DE60309514D1 (de) 2006-12-14
JP5123226B2 (ja) 2013-01-23
ATE386104T1 (de) 2008-03-15
CA2653201C (en) 2011-11-08
JP2009149664A (ja) 2009-07-09
US20050239729A1 (en) 2005-10-27
EP1624053B1 (de) 2006-11-02
ES2300652T3 (es) 2008-06-16
CN101057976B (zh) 2010-05-26
AU2003296892B2 (en) 2006-01-05
ES2275253T3 (es) 2007-06-01
JP2006513993A (ja) 2006-04-27
CN101057976A (zh) 2007-10-24
CN1675353A (zh) 2005-09-28
CN101147807A (zh) 2008-03-26
CA2494888A1 (en) 2004-04-29
CN101147807B (zh) 2010-05-26
EP1543109A4 (de) 2005-10-19
US7381711B2 (en) 2008-06-03
ATE344317T1 (de) 2006-11-15
WO2004034966A2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
ATE344317T1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE527375T1 (de) Diagnose und behandlung von brustkrebs mit scn5a
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
ATE514430T1 (de) Behandlung des alpha-galactosidase a mangels
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EP4225382A4 (de) Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties